Article from Johns Hopkins about a promising potential covid-19 treatment

[rjmacs]

Sarcany wrote:
Someone did the math when that was first announced last week.

It might be useful in edge-cases, but you can't harvest enough antibodies from the survivors to make a dent in those poised to die from the virus.

Hence the rush for monoclonal antibodies.... but they still have to go through all the clinical trial other pharmaceuticals do.